Anticancer agents

DRUG2 trials

Sponsors

Fukuoka University Hospital, BeOne Medicines

Conditions

Advanced Solid TumorPatients with recurrent ovarian cancer

Phase 1

Phase I study using BK-UM against HB-EGF for patients with advanced or recurrent ovarian cancer

RecruitingJPRN-UMIN000001002

Fukuoka University HospitalPatients with recurrent ovarian cancer

Start: 2007-12-01Target: 24Updated: 2026-06-29

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

RecruitingNCT06625593

BeOne MedicinesAdvanced Solid Tumor

Start: 2024-12-09End: 2026-12-31Target: 168Updated: 2026-07-09

Related Papers

Abstract 3778: Preclinical evaluation of BG-C137, a potential first-in-class FGFR2b-targeting ADC, for the treatment of FGFR2b-expressing cancer

Cancer Research2025-04-21

BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study.

2017-01-317 citations